Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — Investor Day (December 2020)

34 slides from Aspen Pharmacare's investor day presentation, Dec 11, 2020

  1. Slide 1: Investor Presentation

    Investor Presentation 11 December 2020

  2. Slide 2: Disclaimer

    DISCLAIMER 2 CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.

  3. Slide 3: Aspen Today

    ASPEN TODAY 3 23 Branded, Supplying Manufacturing specialty medicines to facilities portfolio 150 countries

  4. Slide 4: Reshaping Aspen

    RESHAPING ASPEN 4 WE HAVE SUCCESSFULLY REPOSITIONED ASPEN FOR SUSTAINABLE GROWTH WHERE WE WERE (FY 2013) WHERE WE ARE TODAY Specialty product portfolio comprising leading Commodity generic focussed product portfolio Regional and Sterile Brands Leading global steriles manufacturer & enhanced tabletin

  5. Slide 5: Strong fundamentals for organic growth

    STRONG FUNDAMENTALS FOR ORGANIC GROWTH 5 RESHAPED ASPEN’S ENHANCED COMMERCIAL ORGANIC MANUFACTURING PHARMA GROWTH CAPACITIES MODEL DRIVERS & CAPABILITIES Commercial Pharma Fundamentals Manufacturing Fundamentals Focussed on territories with strong demographic Increasing demand for quality sterile ma

  6. Slide 6: FY 2020 revenue contribution by business segment

    FY 2020 REVENUE CONTRIBUTION BY BUSINESS SEGMENT 6 ADJUSTED TO EXCLUDE DISCONTINUED OPERATIONS REGIONAL BRANDS STERILE BRANDS MANUFACTURING 28% 22% R16.7 bn 50% R9.7 bn R7.3 bn 19% API Chem API Bio-Chem Total FY 2020 revenue after discontinued operations R33.7 billion 15% FDF 66% Growth on prior yea

  7. Slide 7: FY 2020 revenue contribution by geographic segment

    FY 2020 REVENUE CONTRIBUTION BY GEOGRAPHIC SEGMENT 7 ADJUSTED TO EXCLUDE DISCONTINUED OPERATIONS AFRICA MIDDLE EAST * AUSTRALASIA* ASIA*# 12% 13% 25% AMERICAS *ǂ EUROPE CIS *◦ MANUFACTURING 12% 16% 22% *Commercial Pharma #Asia includes China, and Other Asia ǂAmericas includes Latam, USA and Canada ◦

  8. Slide 8: Regional Brands Strategic Positioning

    REGIONAL BRANDS STRATEGIC POSITIONING

  9. Slide 9: Aspen's Regional Brands

    ASPEN’S REGIONAL BRANDS 9 AFRICA MIDDLE EAST AUSTRALASIA ​ AMERICAS​ BRANDS​ BRANDS​ BRANDS​ Mybulen Coloxyl Pentrexyl Flutex Gastro-Stop Magnesia Phillips Panamor Gel Cartia Cofal Movicol Circadin Zyloprim Ulsanic Sigmacort Florinef Tribuss Trustan Eltroxin A DIVERSE PORTFOLIO OF QUALITY AFFORDABLE

  10. Slide 10: Regional Brands

    REGIONAL BRANDS 10 ORGANIC GROWTH + LICENSING OPPORTUNITIES + INTERNAL PIPELINE + BOLT ON ACQUISITIONS Leading positions in South Africa & Australasia  About 60% of revenue comes from SA, Australasia Regional Brands revenue FY 2020 Rebased R16 741 million » Established brand equity in OTC/Consumer,

  11. Slide 11: Regional Brands | Continued

    REGIONAL BRANDS | CONTINUED 11 ORGANIC GROWTH + LICENSING OPPORTUNITIES + INTERNAL PIPELINE + BOLT-ON ACQUISITIONS Increasing relevance and positive growth record in Latin America and the balance of Africa Middle East  Driven by active sales representation  Potential for further leverage of intell

  12. Slide 12: Sterile Brands Strategic Positioning

    STERILE BRANDS STRATEGIC POSITIONING

  13. Slide 13: Aspen's Sterile Brands

    ASPEN’S STERILE BRANDS 13 GENERAL LOCAL ANAESTHETICS TOPICAL ANAESTHETICS THROMBOSIS ANAESTHETICS BRANDS BRANDS BRANDS BRANDS Diprivan Carbocaine Xyloproct Fraxiparine Ultiva Marcain Xylocaine Orgaran Mivacron Citanest Arixtra Nimbex Xylocard Tracrium Naropeine A BROAD RANGE OF STERILE BRANDS FOR US

  14. Slide 14: Sterile Brands – Positioned for Growth

    STERILE BRANDS – POSITIONED FOR GROWTH 14 EXPOSED TO ATTRACTIVE GROWING MARKETS + COGS EFFICIENCIES FROM IN-HOUSE MANUFACTURE Sterile Brands – a portfolio of established Anaesthetics & Thrombosis Brands Sterile Brands revenue FY 2020 Rebased  Anaesthetics over 80% of revenue, has favourable underly

  15. Slide 15: Anaesthetics Product Category Characteristics

    ANAESTHETICS PRODUCT CATEGORY CHARACTERISTICS 15 PRODUCT CATEGORIES ALIGNED TO SITES OF MANUFACTURE GENERAL LOCAL TOPICAL PE NDB BO Diprivan, Ultiva, Carbocaine, Marcaine, Emla, Xylocaine, Mivacron, Nimbex, Citanest, Xylocard, Xyloproct Tracrium Naropin, Xylocaine • High volume products requiring •

  16. Slide 16: Sterile Brands – Delivery of COGS Savings

    STERILE BRANDS – DELIVERY OF COGS SAVINGS 16 R800 MILLION IN SAVING IN COST OF GOODS FROM THE IN-HOUSE MANUFACTURING OF ANAESTHETICS BRANDS COMMERCIAL FY 2021 FY 2022 FY 2023 FY 2024 TRANSFER Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 SITE TRANSFER GENERAL ANA PE SITE TRANSFER LOCAL ANA NDB SIT

  17. Slide 17: Commercial Pharma Summary

    COMMERCIAL PHARMA SUMMARY aspen Healthcare. We Care.

  18. Slide 18: Commercial Pharma Strategic Positioning Summary

    COMMERCIAL PHARMA STRATEGIC POSITIONING SUMMARY 18 Regional Brands  Underlying growth in Aspen territories  South Africa and Australia are largest contributors to revenue » Proven performance and established as leading players  Positive growth potential in expanding territories of Latin America,

  19. Slide 19: Manufacturing Strategic Positioning

    MANUFACTURING STRATEGIC POSITIONING

  20. Slide 20: Manufacturing – Embedding a Safety Culture

    MANUFACTURING – EMBEDDING A SAFETY CULTURE 20 Environment and safety is managed as an integral part of our business  Key performance indicators included in site performance measurement  All fully commercialised primary manufacturing systems and all significant API facilities hold ISO 45001 or OHSA

  21. Slide 21: Manufacturing API – Chem

    MANUFACTURING API – CHEM 21 STABLE BUSINESS SEGMENT WITH POSITIVE GROWTH PROSPECTS Outlook  Portfolio: > 40 different and complex APIs  Stable and predictable sales denominated in EUR and USD » Steroids, hormones, peptides, muscle relaxants, narcotics,  Post-COVID, many pharma companies now wanti

  22. Slide 22: Manufacturing API – Biochem

    MANUFACTURING API – BIOCHEM 22 TRANSFORMING INTO A THIRD PARTY BUSINESS  Biochem is a commodity business. Heparin is the dominant product, others being danaparoid and HcG  Aspen has historically stockpiled significant heparin to give supply and cost certainty to our commercial Thrombosis business

  23. Slide 23: Manufacturing FDF – Sterile Manufacturing Strategy

    MANUFACTURING FDF – STERILE MANUFACTURING STRATEGY 23 CATALYST FOR ACCELERATION OF PROFITABLE GROWTH Current capex project by site R5.8 billion Capacity utilisation intention for the sterile capex 6% BO 30% 30% Additional capacity NDB 28% Aspen Anaesthetics brands PE Third-party products 66% 40%  E

  24. Slide 24: Manufacturing FDF - Third Party Opportunity

    MANUFACTURING FDF - THIRD PARTY OPPORTUNITY 24 PHASE 1 TARGET OF AT LEAST R1.5 BILLION EBITDA BENEFIT FROM THIRD-PARTY CONTRACTS BY FY 2024  Significant capacity available at both PE and NDB. The Third Party OPPORTUNITIES TO FILL CAPACITY WITH THIRD PARTY VOLUMES opportunities are predominantly in

  25. Slide 25: Financial

    FINANCIAL aspen Healthcare. We Care.

  26. Slide 26: Restatement of FY 2020 Revenue Base

    RESTATEMENT OF FY 2020 REVENUE BASE 26 R’million FY 2020 Discontinued FY 2020 Reported operations (restated base) adjustments Commercial Pharmaceuticals 31 144 (4 780) 26 3641 Africa Middle East 8 499 (132) 8 367  Discontinued operations adjustments include Americas 3 996 - 3 996 » Divestment and A

  27. Slide 27: FY 2020 EBITDA Rebased

    FY 2020 EBITDA REBASED 27 R'million FY 2020 Normalised EBITDA Normalised EBITDA 10 968 Discontinued operations adjustment (1 384) Adjusted Normalised EBITDA (continuing operations) 9 584 Europe Oncology pricing adjustment (379) Mylan Thrombosis supply contract (FDF Manufacturing) - Adjusted Normalis

  28. Slide 28: FY 2024 Financial Targets

    FY 2024 FINANCIAL TARGETS 28 EBITDA growth rate over 4 years > Revenue growth rate  Rebased FY 2020 Group EBITDA % = 25.8%* » Diluted by Mylan supply contract  COGS savings of R800 million from bringing Anaesthetics manufacture in-house  Added EBITDA benefit from FDF Manufacturing of at least R1.

  29. Slide 29: Capital Allocation Prioritisation

    29 CAPITAL ALLOCATION PRIORITISATION SUBJECT TO LEVERAGE CAP OF 3.0X AND SUPPORTED BY INCREASING FREE CASH FLOWS PPE capex and Bolt-on acquisitions of Dividends Strategic M&A IP development IP and businesses* Ensure business Large M&A sustainability and Inherent to renewal of transactions that are e

  30. Slide 30: Closing Remarks

    CLOSING REMARKS

  31. Slide 31: FY 2024 Growth Outlook

    FY 2024 GROWTH OUTLOOK 31 Foundation of predictable growth  Commercial Pharma + API Chemicals » 4 year organic CAGR* in CER revenue of between 3% and 7% New opportunity  API Biochem » Transition from predominately a cost centre (internal requirements) to a profit centre focused on selling to Third

  32. Slide 32: M&A Opportunities

    M&A OPPORTUNITIES 32 Aspen has strong relationships with many multinationals  Built of many years of delivery on transactional and manufacturing commitments  Sterile manufacturing offering adds further opportunities to expand these relationships » J&J agreement is an endorsement of our experience

  33. Slide 33: Strategic Positioning

    STRATEGIC POSITIONING 33 BRANDED, SPECIALTY COMPLEX MANUFACTURING EXTENSIVE COMMERCIAL PRODUCT PORTFOLIO CAPABILITIES FOOTPRINT Sterile & Regional FDF & API Covering more than 50 countries Ongoing portfolio renewal through Leverage of installed capacity creates Delivering predictable annuity develop

  34. Slide 34: °) ASPEN Healthcare. We Care.

    °) ASPEN Healthcare. We Care.

Aspen Pharmacare Holdings — Investor Day (December 2020) on 6ix